870 related articles for article (PubMed ID: 7543114)
1. Continuous infusion versus daily injections of growth hormone (GH) for 4 weeks in GH-deficient patients.
Laursen T; Jørgensen JO; Jakobsen G; Hansen BL; Christiansen JS
J Clin Endocrinol Metab; 1995 Aug; 80(8):2410-8. PubMed ID: 7543114
[TBL] [Abstract][Full Text] [Related]
2. Long-term effects of continuous subcutaneous infusion versus daily subcutaneous injections of growth hormone (GH) on the insulin-like growth factor system, insulin sensitivity, body composition, and bone and lipoprotein metabolism in GH-deficient adults.
Laursen T; Gravholt CH; Heickendorff L; Drustrup J; Kappelgaard AM; Jørgensen JO; Christiansen JS
J Clin Endocrinol Metab; 2001 Mar; 86(3):1222-8. PubMed ID: 11238512
[TBL] [Abstract][Full Text] [Related]
3. Metabolic effects of growth hormone administered subcutaneously once or twice daily to growth hormone deficient adults.
Laursen T; Jørgensen JO; Christiansen JS
Clin Endocrinol (Oxf); 1994 Sep; 41(3):337-43. PubMed ID: 7525120
[TBL] [Abstract][Full Text] [Related]
4. Pulsatile versus continuous intravenous administration of growth hormone (GH) in GH-deficient patients: effects on circulating insulin-like growth factor-I and metabolic indices.
Jørgensen JO; Møller N; Lauritzen T; Christiansen JS
J Clin Endocrinol Metab; 1990 Jun; 70(6):1616-23. PubMed ID: 2189886
[TBL] [Abstract][Full Text] [Related]
5. Two weeks of daily injections and continuous infusion of recombinant human growth hormone (GH) in GH-deficient adults: I. Effects on insulin-like growth factor-I (IGF-I), GH and IGF binding proteins, and glucose homeostasis.
Johansson JO; Oscarsson J; Bjarnason R; Bengtsson BA
Metabolism; 1996 Mar; 45(3):362-9. PubMed ID: 8606645
[TBL] [Abstract][Full Text] [Related]
6. Effects of octreotide on insulin-like growth factor I and metabolic indices in growth hormone-treated growth hormone-deficient patients.
Laursen T; Jørgensen JO; Orskov H; Møller J; Harris AG; Christiansen JS
Acta Endocrinol (Copenh); 1993 Nov; 129(5):399-408. PubMed ID: 7506470
[TBL] [Abstract][Full Text] [Related]
7. Evening versus morning injections of growth hormone (GH) in GH-deficient patients: effects on 24-hour patterns of circulating hormones and metabolites.
Jørgensen JO; Møller N; Lauritzen T; Alberti KG; Orskov H; Christiansen JS
J Clin Endocrinol Metab; 1990 Jan; 70(1):207-14. PubMed ID: 2294131
[TBL] [Abstract][Full Text] [Related]
8. Short-term changes in serum insulin-like growth factors (IGF) and IGF binding protein 3 after different modes of intravenous growth hormone (GH) exposure in GH-deficient patients.
Jørgensen JO; Blum WF; Møller N; Ranke MB; Christiansen JS
J Clin Endocrinol Metab; 1991 Mar; 72(3):582-7. PubMed ID: 1705258
[TBL] [Abstract][Full Text] [Related]
9. Bioavailability and bioactivity of intravenous vs subcutaneous infusion of growth hormone in GH-deficient patients.
Laursen T; Møller J; Jørgensen JO; Orskov H; Christiansen JS
Clin Endocrinol (Oxf); 1996 Sep; 45(3):333-9. PubMed ID: 8949572
[TBL] [Abstract][Full Text] [Related]
10. Stimulation of the 150-kilodalton insulin-like growth factor-binding protein-3 ternary complex by continuous and pulsatile patterns of growth hormone (GH) administration in GH-deficient patients.
Laursen T; Flyvbjerg A; Jørgensen JO; Baxter RC; Christiansen JS
J Clin Endocrinol Metab; 2000 Nov; 85(11):4310-4. PubMed ID: 11095473
[TBL] [Abstract][Full Text] [Related]
11. Growth hormone (GH) replacement in GH-deficient adults: a crossover trial comparing the effect on metabolic control, well-being and compliance of three injections per week versus daily injections.
Johansson JO; Wirén L; Oscarsson J; Bengtsson BA; Johannsson G
Growth Horm IGF Res; 2003 Dec; 13(6):306-15. PubMed ID: 14624763
[TBL] [Abstract][Full Text] [Related]
12. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.
Khorram O; Laughlin GA; Yen SS
J Clin Endocrinol Metab; 1997 May; 82(5):1472-9. PubMed ID: 9141536
[TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factors (IGF) I and II and IGF binding proteins 1, 2 and 3 during low-dose growth hormone (GH) infusion and sequential euglycemic and hypoglycemic glucose clamps: studies in GH-deficient patients.
Jørgensen JO; Blum WF; Horn N; Møller N; Møller J; Ranke MB; Christiansen JS
Acta Endocrinol (Copenh); 1993 Jun; 128(6):513-20. PubMed ID: 7687807
[TBL] [Abstract][Full Text] [Related]
14. Impact of moderate interval exercise versus supine rest on the pharmacokinetics and pharmacodynamic profiles of subcutaneously administered growth hormone in adult growth hormone deficient patients.
Janukonytė J; Parkner T; Lauritzen T; Christiansen JS; Frystyk J; Pedersen HS; Laursen T
Growth Horm IGF Res; 2014 Oct; 24(5):198-204. PubMed ID: 25037883
[TBL] [Abstract][Full Text] [Related]
15. Bioavailability and bioactivity of three different doses of nasal growth hormone (GH) administered to GH-deficient patients: comparison with intravenous and subcutaneous administration.
Laursen T; Grandjean B; Jørgensen JO; Christiansen JS
Eur J Endocrinol; 1996 Sep; 135(3):309-15. PubMed ID: 8890721
[TBL] [Abstract][Full Text] [Related]
16. Levels of growth hormone, insulin-like growth factor-I (IGF-I) and -II, IGF-binding protein-1 and -3, and cortisol in prednisone-treated children with growth retardation after renal transplantation.
Hokken-Koelega AC; Stijnen T; de Muinck Keizer-Schrama SM; Blum WF; Drop SL
J Clin Endocrinol Metab; 1993 Oct; 77(4):932-8. PubMed ID: 7691864
[TBL] [Abstract][Full Text] [Related]
17. Administration of growth hormone (GH), but not insulin-like growth factor-I (IGF-I), by continuous infusion can induce the formation of the 150-kilodalton IGF-binding protein-3 complex in GH-deficient rats.
Gargosky SE; Tapanainen P; Rosenfeld RG
Endocrinology; 1994 May; 134(5):2267-76. PubMed ID: 7512499
[TBL] [Abstract][Full Text] [Related]
18. Effects of a 7-day continuous infusion of octreotide on circulating levels of growth factors and binding proteins in growth hormone (GH)-treated GH-deficient patients.
Laursen T; Møller J; Fisker S; Jorgensen JO; Christiansen JS
Growth Horm IGF Res; 1999 Dec; 9(6):451-7. PubMed ID: 10629166
[TBL] [Abstract][Full Text] [Related]
19. Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease.
Fernholm R; Bramnert M; Hägg E; Hilding A; Baylink DJ; Mohan S; Thorén M
J Clin Endocrinol Metab; 2000 Nov; 85(11):4104-12. PubMed ID: 11095440
[TBL] [Abstract][Full Text] [Related]
20. Altered relation between circulating levels of insulin-like growth factor-binding protein-1 and insulin in growth hormone-deficient patients and insulin-dependent diabetic patients compared to that in healthy subjects.
Hilding A; Brismar K; Degerblad M; Thorén M; Hall K
J Clin Endocrinol Metab; 1995 Sep; 80(9):2646-52. PubMed ID: 7545695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
